Status:
ENROLLING_BY_INVITATION
Effects of Breakfast Glycaemic Index on Cognition in Earlier or Later Chronotypes.
Lead Sponsor:
Anette Buyken
Collaborating Sponsors:
Paderborn University
University of Southern Denmark
Conditions:
Healthy
Eligibility:
All Genders
18-25 years
Phase:
NA
Brief Summary
High glycaemic index (GI) breakfasts resulting in sharp rises in blood glucose may adversely affect memory and attention, particularly in the late postprandial phase (i.e., 120-180 minutes after break...
Detailed Description
Background Studies in young adults indicate beneficial effects of a low glycemic index (GI) breakfast on cognitive performance. A meta-analysis of 17 studies revealed benefits of a low-glycemic load (...
Eligibility Criteria
Inclusion
- Participants of GlyCoBrain Observational Study
- Early or late chronotype (approx. lowest and highest quartile)
Exclusion
- Students studying nutritional science and home economics (study programs of the study PI)
- Intermediate chronotypes
- Persons unwilling to abstain from smoking or cannabis use during the intervention period
- Persons unwilling to consume standard evening meal prior to intervention days
- BMI\>30 kg/m² (diurnal variation in glycaemic control is known to be absent among persons with obesity) and \<18.5 kg/m2 (since underweight is also known to affect glucose homeostasis)
- acute or permanent use of sleep-promoting medications (including herbal preparation):
- medications: melatonin, diphenhydramine, doxylamine
- herbal preparations: hops, St. John's wort, lemon balm, lavender, passionflower, Baldurat, Neurexan, cannabinoids
- Use of psychotropic medications (antidepressants, tranquilizer, antipsychotics)
- Use of methylphenidate (e.g. Ritalin, Medikinet, Concerta)
- Use of cannabinoids by prescription
- Continuous administration of antihistamines when discontinuation is not feasible during the intervention
- Use of herbal preparations affecting memory and concentration (e.g. gingko, ginseng, ashwagandha)
- Use of other medications (e.g. insulin, metformin, SGLT2 inhibitors, steroids, ACE inhibitors)
- Selected chronic diseases (depression and other mental disorders such as anxiety disorder, ADHD, diabetes mellitus (all types), prediabetes, blood clotting disorders (e.g., thrombocytopenia, hemophilia), eating disorders (e.g., anorexia, binge eating, bulimia), Chronic inflammatory bowel diseases, infectious diseases (HIV, hepatitis), Addiction disorders (e.g., alcohol, drug, or medication dependency)
- Pregnant and breastfeeding individuals
- Shift work or travel in the past 3 months across more than 2 time zones
- students with a pacemaker/defibrillator or cochlear implant
Key Trial Info
Start Date :
April 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT06916039
Start Date
April 4 2025
End Date
July 31 2027
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Paderborn University
Paderborn, North Rhine-Westphalia, Germany, 33098